Get started
Author

Lawrence Severt

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
2014 · The Parkinson Study Group QE3 Investigators, M. Flint Beal, et al. · JAMA Neurology · 410
PDF
Atogepant for the Preventive Treatment of Migraine
2021 · Jessica Ailani, Richard B. Lipton, et al. · New England Journal of Medicine · 314
PDF
Age-specific penetrance ofLRRK2G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium
2015 · Karen Marder, Yuanjia Wang, et al. · Neurology · 161
PDF
Validity of spiral analysis in early Parkinson's disease
2007 · Rachel Saunders‐Pullman, Carol Derby, et al. · Movement Disorders · 148
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 · Patricia Pozo-Rosich, Jessica Ailani, et al. · The Lancet · 143
Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations
2013 · Roy N. Alcalay, Anat Mirelman, et al. · Movement Disorders · 139
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study
2019 · Tanya Simuni, Liz Uribe, et al. · The Lancet Neurology · 131
Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
2020 · Jessica Ailani, Richard B. Lipton, et al. · Headache The Journal of Head and Face Pain · 100
PDF
Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [18F]Fluorodeoxyglucose Positron Emission Computed Tomography Study
2013 · Chaorui Huang, Lisa D. Ravdin, et al. · Dementia and Geriatric Cognitive Disorders · 100
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA
2023 · David W Dodick, Peter J Goadsby, et al. · The Lancet · 94
Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers
2014 · Rick C. Helmich, Avner Thaler, et al. · Neurology · 73
PDF
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease
2010 · Rachel Saunders‐Pullman, Matthew J. Barrett, et al. · Movement Disorders · 69
Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial
2023 · Messoud Ashina, Stewart J. Tepper, et al. · Headache The Journal of Head and Face Pain · 66
PDF
Dystonia treatment
2017 · Sarah Pirio Richardson, Ashley R. Wegele, et al. · Neurology · 66
PDF
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers
2012 · Avner Thaler, Anat Mirelman, et al. · Neurology · 63
PDF
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
2021 · Todd J Schwedt, Richard B Lipton, et al. · Cephalalgia · 61
PDF
Olfactory dysfunction in LRRK2 G2019S mutation carriers
2011 · R. Saunders-Pullman, K. Stanley, et al. · Neurology · 61
PDF
Clinical and genetic features of cervical dystonia in a large multicenter cohort
2016 · Mark S. LeDoux, Satya R. Vemula, et al. · Neurology Genetics · 52
PDF
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults
2019 · Peter J Goadsby, Stewart J Tepper, et al. · Cephalalgia · 47
Digitized spiral analysis is a promising early motor marker for Parkinson Disease
2010 · Kaili Stanley, Johann Hagenah, et al. · Parkinsonism & Related Disorders · 44
PDF
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II
2021 · Susan Hutchinson, Stephen D Silberstein, et al. · Cephalalgia · 37
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
2022 · Richard B. Lipton, Patricia Pozo-Rosich, et al. · Neurology · 32
PDF
Glucocerebrosidase enzyme activity in GBA mutation Parkinson’s disease
2016 · Roberto A. Ortega, Paola A. Torres, et al. · Journal of Clinical Neuroscience · 31
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
2023 · Brad C Klein, Rosa Miceli, et al. · Cephalalgia · 24
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults
2022 · Richard B. Lipton, Patricia Pozo-Rosich, et al. · JAMA Network Open · 21
PDF
Works count: 71
Citation count: 2,612
H-index: 24
I10-index: 30
Year
Topic
Type